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Abstract
Background: Late gadolinium enhancement (LGE) occurs at the right ventricular (RV) insertion point (RVIP) in
patients with pulmonary hypertension (PH) and has been shown to correlate with cardiovascular magnetic
resonance (CMR) derived RV indices. However, the prognostic role of RVIP-LGE and other CMR-derived parameters
of RV function are not well established. Our aim was to evaluate the predictive value of contrast-enhanced CMR in
patients with PH.
Methods: RV size, ejection fraction (RVEF), and the presence of RVIP-LGE were determined in 58 patients with PH
referred for CMR. All patients underwent right heart catheterization, exercise testing, and N-terminal pro-brain
natriuretic peptide (NT-proBNP) evaluation; results of which were included in the final analysis if performed within
4 months of the CMR study. Patients were followed for the primary endpoint of time to clinical worsening (death,
decompensated right ventricular heart failure, initiation of prostacyclin, or lung transplantation).
Results: Overall, 40/58 (69%) of patients had RVIP-LGE. Patients with RVIP- LGE had larger right ventricular volume
index, lower RVEF, and higher mean pulmonary artery pressure (mPAP), all p < 0.05. During the follow-up period of
10.2 ± 6.3 months, 19 patients reached the primary endpoint. In a univariate analysis, RVIP-LGE was a predictor for
adverse outcomes (p = 0.026). In a multivariate analysis, CMR-derived RVEF was an independent predictor of clinical
worsening (p = 0.036) along with well-established prognostic parameters such as exercise capacity (p = 0.010) and
mPAP (p = 0.001).
Conclusions: The presence of RVIP-LGE in patients with PH is a marker for more advanced disease and poor
prognosis. In addition, this study reveals for the first time that CMR-derived RVEF is an independent non-invasive
imaging predictor of adverse outcomes in this patient population.
Background
Significant advances in our understanding of the patho-
physiology of pulmonary hypertension (PH) have led to
several therapies that have improved quality of life and
decreased mortality. Indeed, in this decade, 1-year survi-
val rate is 85% versus 68% in the 1980s [1]. Despite this
relative improvement in short-term survival, the prog-
nosis of patients with PH remains poor [2]. Clinical man-
agement of these patients is driven, in part, by the ability
t op r e d i c ts u r v i v a l ,b u tr e c e n te f f o r t st op r e d i c t1 - y e a r
survival in patients with pulmonary arterial hypertension
have not incorporated multiple non-invasive parameters
such as right ventricular (RV) size and function [3].
Due to its relatively high intra- and inter-observer
reproducibility, many have advocated the use of cardio-
vascular magnetic resonance (CMR) over echocardiogra-
phy as a non-invasive way to predict outcomes and
assess the effects of medical therapy on RV function
over time [4-6]. Recently, several studies have high-
lighted the potential utility of CMR in patients with PH
a f t e rd i s c o v e r i n gt h ep r e s e n c eo fl a t eg a d o l i n i u m
enhancement (LGE) in the right ventricular insertion
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majority of these patients [7-11]. These studies sug-
gested a significant inverse correlation between the
degree of RVIP-LGE and right ventricular ejection frac-
tion (RVEF) and hemodynamics.
While previous publications focused on the existence
of RVIP-LGE in patients with PH and its association
with multiple indices of RV failure, our study sought to
investigate the potential role of RVIP-LGE and other
CMR-derived parameters of RV function as non-invasive
predictors of death, decompensated RV heart failure,
initiation of prostacyclin or lung transplantation. Specifi-
cally, we hypothesized that: 1) the presence of RVIP-
LGE significantly correlates with both the hemodynamic
parameters of PH and associated RV findings, and 2)
RV function, including RVIP-LGE, can be used to pre-
dict time to clinical worsening in patients with PH.
Methods
Study population and design
We evaluated 62 consecutive patients with PH referred
for CMR as part of their clinical assessment between
January 2009 and July 2010. Patients were excluded if
they had an implantable cardioverter defibrillator or
pacemaker, were claustrophobic, other contra-indication
to CMR, or had a GFR of less than 30 ml/min/1.73 m
2.
All patients underwent right heart catheterization, exer-
cise testing and measurement of N-terminal pro brain
natriuretic peptide (NT-proBNP), but the results of
these tests were included in the final analysis only if
they were performed within 4 months of their CMR
evaluation. Each patient underwent a thorough clinical
evaluation by one of two physicians with expertise in
PH (MG and SR), in which World Health Organization
(WHO) functional status [12] was assessed and medica-
tions documented. The etiology of PH was recorded and
classified according to the WHO schema [13]. Patient
characteristics are summarized in Table 1 and Table 2
Medical records were reviewed for the primary end-
point of time to clinical worsening. Time to clinical
worsening includes 1) all cause mortality 2) hospitaliza-
tion due to clinically decompensated right ventricular
heart failure requiring IV therapy 3) initiation of prosta-
cyclin or 4) lung transplantation. All deaths were con-
firmed by the social security death index. Whenever
possible, the causes for hospitalization and death were
recorded. The study was approved by the Institutional
Review Board. While patients were prospectively tracked
from the time of their CMR study to the primary end
point or completion of study, hemodynamic data, func-
tional analysis and NT-proBNP were retrospectively
obtained in order to include a reasonably comprehen-
sive, clinically relevant dataset in as many patients with
PH as possible.
CMR
CMR images were acquired on a 1.5-T scanner
(Achieva, Philips, Best, Netherlands). Retrospectively
gated cine images were obtained using the steady-state
free precession (SSFP) sequence (TR 2.9 ms, TE 1.5 ms,
flip angle 60°, and temporal resolution ~40 ms). Stan-
dard long-axis views were obtained, including four-
chamber, two-chamber, and three-chamber images. In
addition, one series of short axis slices that included
both right and left ventricles from base to apex were
acquired and a series of axial cines were acquired in
order to determine atrial volumes. LGE images of the
short and long axis views were obtained 10 minutes
after infusion of gadolinium-diethylene triamine-pentaa-
cetic acid (Gd-DTPA 0.2 mmol/kg) using T1-weighted
gradient echo pulse sequence with a phase sensitive
inversion recovery reconstruction (TR 4.5 ms, TE 2.2
ms, TI 250-300 ms, flip angle 30°, flip angle 5°, voxel
size 2 × 2 × 10 mm, SENSE factor 2). An inversion time
between 250 and 300 ms generally achieved successful
nulling of the myocardium. During image acquisition,
suspected partial volume and other artifacts seen on the
LGE images were accounted for by either directly com-
paring the LGE image with an SSFP cine image taken at
the same slice position or by swapping phase-encoding
and frequency-encoding directions. If the existence of
LGE was still in doubt, a second imaging plane was pre-
scribed directly through the area of interest for further
clarification.
Table 1 Clinical characteristics of patient population
All patients (n = 58)
Demographics
Age (years) 53 ± 14
Women, n(%) 43 (74%)
Time of PH Diagnosis
Prior to CMR study 38 (66%)
After CMR study 20 (34%)
WHO Categorizations
WHO Group I 44 (76%)
Idiopathic PAH 24
Associated PAH 20
WHO Group II 8 (14%)
WHO Group III 1 (1.7%)
WHO Group IV 2 (3.4%)
WHO Group V 3 (5.2%)
Medications at time of CMR
Prostacyclin analogs ± other* PH medications 18 (31%)
Other* PH medications only 18 (31%)
No PH medications 22 (38%)
*Other medications include endothelin receptor antagonists, calcium channel
blockers, phosphodiesterase inhibitors, and multikinase inhibitors (sorafenib)
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Images were analyzed using commercial software (Phi-
lips ViewForum, Best, Netherlands). Short axis slices
were used to calculate left and right ventricular end-dia-
stolic (first cine phase of the R wave triggered acquisi-
tion) and end-systolic (image phase with the smallest
ventricular cavity area in the majority of slices) volumes,
masses, and ejection fractions by the Simpson method
of disks [14]. Left and right atrial volumes were calcu-
lated using the ventricular end-systolic frame from the
axial cines. All volumes and masses were indexed for
body surface area. The interventricular septum was con-
sidered part of the left ventricle for left ventricular mass
calculation purposes. LGE of the myocardium was
visually assessed by a CMR expert blinded to hemody-
namic, functional, and laboratory data. LGE was consid-
ered to be present if the signal intensity in the
myocardium at the RVIP was greater than or equal to
that seen in the blood pool, present in 2 consecutive
slices, and clearly present within the myocardium when
compared against a matching SSFP cine image.
Right heart catheterization
Although all patients had a right heart catheterization to
initially diagnose PH, a subgroup of them underwent right
heart catheterization (using a Swan-Ganz catheter) within
4 months their CMR study. Hemodynamics and mixed
venous oxygen saturation were obtained. Cardiac output
and index were calculated using the thermodilution tech-
nique. Pulmonary vascular resistance and right ventricular
stroke work were recorded by standard formula.
N-terminal pro-brain natriuretic peptide
Although a majority had an NT-proBNP drawn at some
point during their PH evaluation, NT-proBNP was mea-
sured in a subgroup of patients using a commercially
available assay (Roche, Indianapolis, IN) within 4
months of their CMR study.
Table 2 Comparison between diagnostic characteristics of patients with and without late gadolinium enhancement
(LGE)
CMR All patients (n = 58) Patients with LGE (n =
40)
Patients without LGE (n =
18)
p
value
Right ventricular end-diastolic volume index (ml/
m2)
128 ± 57 137 ± 55 101 ± 55 0.03
Right ventricular end-systolic volume index (ml/m2) 84 ± 56 94 ± 53 57 ± 55 0.03
Right ventricular ejection fraction (%) 38 ± 15 35 ± 13 48 ± 14 < 0.01
Right ventricular mass index (g/m2) 27 ± 13 31 ± 13 19 ± 12 < 0.01
Right ventricular stroke volume (ml) 81 ± 26 81 ± 27 80 ± 22 0.98
Right atrial volume (ml) 133 ± 59 139 ± 59 112 ± 49 0.10
Right ventricular stroke work (mmHg × ml) 3776 ± 1766 3410 ± 2192 1934 ± 1581 0.02
Left ventricular end-diastolic volume index (ml/m2) 72 ± 27 72 ± 30 76 ± 21 0.51
Left ventricular end-systolic volume index (ml/m2) 32 ± 21 33 ± 22 33 ± 21 0.94
Left ventricular ejection fraction (%) 57 ± 10 56 ± 9.5 59 ± 11 0.34
Left ventricular mass index (g/m2) 41 ± 15 43 ± 17 37 ± 12 0.11
Left atrial volume (ml) 70 ± 33 65 ± 32 83 ± 33 0.06
Naughton-Balke Exercise Treadmill Test All patients* (n =
42)
Patients with LGE (n =
30)
Patients without LGE (n =
12)
p
value
Metabolic equivalents 5.6 ± 2.3 5.3 ± 2.3 6.5 ± 2.4 0.15
Right Heart Catheterization All patients* (n =
35)
Patients with LGE (n =
27)
Patients without LGE (n = 8) p
value
Mean right atrial pressure (mmHg) 9.8 ± 5.0 10 ± 5.2 7 ± 3.0 0.08
Mean pulmonary artery pressure (mmHg) 49 ± 16 52 ± 16 35 ± 5.8 < 0.01
Pulmonary capillary wedge pressure (mmHg) 12 ± 5.4 12 ± 6.0 13 ± 3.1 0.68
Cardiac index (L/min/m2) 2.6 ± 0.99 2.4 ± 0.85 3.4 ± 1.3 0.08
Pulmonary vascular resistance (Wood Units) 9.5 ± 5.3 10 ± 5.7 5.2 ± 1.1 < 0.01
Mixed venous oxygen saturation (%) 62 ± 15 63 ± 11 66 ± 10 0.52
N-Terminal Pro Brain Natriuretic Peptide All patients* (n =
43)
Patients with LGE (n =
30)
Patients without LGE (n =
13)
p
value
NT-proBNP level (pg/mL) 2100 ± 4862 2334 ± 5316 705 ± 1330 0.13
* Only hemodynamics, METS, and NT-proBNP testing within 4 months of the CMR study were included in analysis.
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A subgroup of patients underwent exercise treadmill
testing performed using the Naughton-Balke protocol
[15], wherein treadmill time (in seconds) was converted
to exercise metabolic equivalents (METs) as described
previously [16]. Tests were interpreted using previously
published sex-specific nomograms for metabolic equiva-
lents [17,18]. Although a majority of patients had an
exercise test performed at some point during their PH
evaluation, only treadmill tests performed within 4
m o n t h so ft h eC M Rs t u d yw e r ei n c l u d e di nt h ef i n a l
analysis.
Statistical analysis
Categorical variables were expressed as percentages
and continuous variables as mean ± standard deviation.
We used an independent sample (unpaired) Student t-
test (equal variances not assumed) to compare the
means of normally distributed continuous variables in
those patients with and without RVIP-LGE. The
Mann-Whitney U test was used to compare the means
for non-normally distributed variables. Categorical
variables were compared using Fisher Exact or Chi-
Square test. P values < 0.05 were considered statisti-
cally significant. In 26 randomly selected patients,
interobserver reproducibility between the primary
reader and an additional investigator was assessed by
means of percent agreement and Cohen’sk a p p a( )
statistic. Cox proportional hazard analysis was per-
formed to assess univariate and multivariate predictors
of clinical worsening. Hazard ratios (HR) and 95% con-
fidence intervals (CI) were calculated. Multivariable
analysis was performed using six variables that were
the most statistically significant in the univariate analy-
sis and satisfied the linearity and proportional hazard
assumptions for linear regression. These variables
include left ventricular end-diastolic volume index,
RVEF, mean pulmonary artery pressure (mPAP),
M E T s ,N T - p r o B N P ,a n dR V I P - L G E .T h ed i s c r i m i n a -
tory capacity of the independent predictors of outcome
was investigated using non-parametric estimates of the
area under the receiver operating characteristic (ROC)
curves. Survival curves for RVIP-LGE and each of the
multivariate predictors of outcome were constructed
with the Kaplan-Meier method and were compared by
means of the log-rank test. The threshold values for
each multivariate predictor of outcome were selected
based on highest specificity and sensitivity as generated
b yt h ep r e v i o u s l ym e n t i o n e dROC curves. All statistical
analyses were performed using Prism (GraphPad Soft-
ware, San Diego, California) or Stata (version 11, Stata-
Corp LP, College Station, Texas). MIX 2.0 software
was used to prepare the forest plot graphs [19].
Results
Patient characteristics
Of the 62 patients, RVIP-LGE was indeterminate in 3
patients due to technical issues resulting in poor signal
to noise ratio and excessive motion artifact in 1 patient.
These 4 patients were not included in the final analysis.
A total of 35 patients underwent right heart catheteriza-
tion, 43 patients underwent NT-proBNP evaluation, and
42 patients underwent exercise stress testing within 4
months of their CMR study. During the mean follow-up
period of 10.2 ± 6.3 months, 19/58 (33%) patients
reached the primary endpoint of time to clinical worsen-
ing: 6 patients died, 11 were hospitalized for decompen-
sated right ventricular heart failure, and 2 patients were
hospitalized for initiation of prostacyclin analog. Of the
patients who reached the primary endpoint, RVIP-LGE
was present in 18/19 (95%). The patient without RVIP-
LGE had sarcoidosis and was hospitalized for PH
exacerbation.
RVIP-LGE and association with invasive and non-invasive
variables
Overall, RVIP-LGE was present in 40/58 (69%) of
patients (Figure 1). In comparing CMR variables (Table
2), patients with RVIP-LGE had significantly larger right
ventricular volumes, lower RVEF, increased right ventri-
cular mass index, and higher right ventricular stroke
work. Patients with RVIP-LGE who underwent right
heart catheterization had significantly higher mPAP and
Figure 1 Late gadolinium enhancement of right ventricular
insertion point. This figure depicts a short axis, late gadolinium
enhanced, phase-sensitive CMR image of the left and right ventricle.
The white block arrows indicate areas of LGE located in both the
anterior and inferior RVIP. The mPAP for this patient at rest during
right heart catheterization was 62 mmHg. LV = left ventricle; RV =
right ventricle.
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sure and cardiac index were not statistically significant;
however, both variables trended in that direction. In
those patients who underwent exercise or NT-proBNP
testing, there was no statistical difference in METs or
NT-proBNP between the patients with RVIP-LGE and
those without.
Reproducibility of RVIP-LGE
There was good interobserver agreement in identifying
the existence of RVIP-LGE between the primary reader
and an additional investigator (88%,  = 0.72).
Univariate and multivariate predictors of mortality
The HR, CI, and statistical significance for all invasive
and non-invasive variables are reported in Figure 2. The
presence of RVIP-LGE was statistically significant for
predicting time to clinical worsening. Other CMR uni-
variate predictors of the primary outcome, in order of
statistical significance, included: RVEF, left atrial
volume, left ventricular end-diastolic volume index,
right ventricular end-systolic volume index, right ventri-
cular end-diastolic volume index, and right ventricular
mass index. Hemodynamic univariate predictors of time
to clinical worsening, in order of statistical significance,
included: mPAP, pulmonary vascular resistance, cardiac
index, and mixed venous oxygen saturation. NT-proBNP
and METs were also significant for predicting the pri-
mary outcome. The multivariate analysis demonstrated
that, after inclusion of six select statistically significant
univariate predictors of time to clinical worsening, only
mPAP (HR 1.14; 95% CI 1.05-1.23; p = 0.001), METs
(HR 0.46; 95% CI 0.25-0.83, p = 0.01), and RVEF (HR
0.91; 95% CI 0.83-0.99, p = 0.036) remained statistically
significant.
Kaplan-Meier survival analysis
Kaplan-Meier survival curves generated for RVIP-LGE
and the three independent predictors of time to clinical
worsening are shown in Figure 3. Patients with RVIP-
LGE were statistically more likely to reach the primary
endpoint than those without the presence of RVIP-LGE
(log-rank test, p = 0.0065). Patients with mPAP ≥ 45
mmHg (log-rank test, p = 0.0001), RVEF less than 39%
(log-rank test, p = 0.0063), or METs ≤ 6.1 (log-rank test,
p = 0.0129) also had a significantly worse prognosis.
Discussion
In this study, we found that in patients with PH, not
only is RVIP-LGE associated with RV dilation and
hypertrophy, reduced RVEF, and more extensive hemo-
dynamic abnormalities, but its presence is also a univari-
ate predictor of time to clinical worsening. Although a
few previous publications have discussed the existence
and extent of RVIP-LGE in patients with PH and its
inverse correlation with RV function, we have demon-
strated in this study that it is also a non-invasive marker
of adverse outcomes. In a multivariate analysis, although
RVIP-LGE is no longer statistically significant, we show
that CMR-derived RVEF is an independent predictor of
Figure 2 Univariate analysis of multiple parameters for right ventricular function. Forest plot of univariate proportional hazards modeling
including hazard ratios, 95% confidence intervals and p-values for parameters obtained from CMR, functional testing, NT-proBNP, and
hemodynamics. The presence of RVIP-LGE was statistically significant for predicting time to clinical worsening. LVEDVI = left ventricular end-
diastolic volume index; LVESVI = left ventricular end-systolic volume index; LVEF = left ventricular ejection fraction; RVEDVI = right ventricular
end-diastolic volume index; RVESVI = right ventricular end-systolic volume index; LA size = left atrial volume; RA size = right atrial volume; Mean
RA Pressure = mean right atrial pressure; PCWP = pulmonary capillary wedge pressure; CI = cardiac index; PVR = pulmonary vascular resistance;
MVO2 = mixed venous oxygen saturation.
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clinical parameters of PH such as mPAP and METs.
Previous publications
In 2005, Blyth et al. reported that 23/25 (92%) of their
patients with PH had RVIP-LGE and that the extent of
LGE was highly correlated with RV volume, RV mass,
mPAP, and inversely correlated with RVEF [7]. A second
study by Sanz et al. found that 41/42 (97%) patients with
PH had evidence of RVIP-LGE while only 3/13 (23%) of
patients without PH had RVIP-LGE [9]. In addition, simi-
lar to Blyth et al., the extent of RVIP-LGE correlated
moderately well with multiple CMR and hemodynamic
parameters of RV dysfunction. In a multivariate analysis,
only systolic PAP predicted the presence of RVIP-LGE.
Another study with 15 patients by McCann et al.
reported the presence of RVIP-LGE in 100% of their PH
patients and also demonstrated a positive correlation
between extent of LGE and other CMR findings of RV
dysfunction [8]. However, unlike Blythe et al. and Sanz et
al., they did not find a significant correlation between the
extent of LGE and hemodynamic parameters of PH,
despite the fact that their cohort of patients had a higher
overall mPAP when compared to the study by Blyth et al.
(54 ± 16 mmHg vs. 43 ± 12 mmHg) and Sanz et al. (54 ±
16 mmHg vs. 44 ± 12). The most recent study examining
RVIP-LGE in patients with PH showed RVIP-LGE in
only 13/20 patients and the only significant correlation
was found between the extent of LGE and the duration
of disease and not with RV size, function, or hemody-
namics [10]. Our study is in agreement with the findings
by Blyth et al. and Sanz et al. but builds on the relatively
small amount of data available on this topic by including
more patients and additionally following them over time.
The prevalence of RVIP-LGE in patients with PH
The prevalence of RVIP-LGE in PH patients is not
clearly defined; in fact, some previous publications have
Figure 3 Time to clinical worsening for patients with pulmonary hypertension. Kaplan-Meier curves demonstrated time to clinical
worsening for (A) patients with and without the presence of RVIP-LGE, (B) patients with RVEF ≥ 39% and < 39%, (C) patients with mPAP ≥ 45
mmHg and < 45 mmHg, and (D) patients with METs ≥ 6.1 and < 6.1.
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population, approximately two-thirds of patients had
RVIP-LGE. The 18 patients without RVIP-LGE had
higher RVEF and lower mPAP suggesting less severe
disease. Therefore, unlike the results of previous studies,
the wider variety of PH etiologies (as reflected by inclu-
sion of patients from all 5 WHO groups) and greater
spectrum of disease severity in our patient cohort
showed that RVIP-LGE is not necessarily a ubiquitous
marker for PH but rather is more directly related to
reduced RV function and, hence, disease severity.
Non-invasive predictors of outcome
Since the presence of RVIP-LGE is highly associated with
reduced RV function, we followed all patients for an aver-
age of 10 months and found that patients with RVIP-LGE
were ten times more likely to reach the primary endpoint
of clinical worsening than those patients without RVIP-
LGE. While significantly predictive in a univariate analysis,
the presence of RVIP-LGE was not an independent predic-
tor of poor outcomes in a multivariable analysis likely due
to its strong association with other variables included in
the model. However, the data suggest that it is a strong
marker for detecting more severe disease manifested by
higher mPAP and lower RVEF and functions as a simple,
binary, reproducible, and visible reflection of these inde-
pendent predictors of clinical worsening. Furthermore, the
absence of RVIP-LGE predicted 100% survival in 14
months whereas only half of the patients with evidence of
RVIP-LGE were alive or free from hospitalization or pros-
tacyclin initiation in the same time frame.
In our patient cohort, RVEF was the only independent
prognostic variable obtained from the CMR examina-
tion. We also confirm previous reports [20] that mPAP
and METs were independent predictors of poor prog-
nosis. Our results are consistent with previous studies
showing that RVEF is, indeed, a powerful predictor of
adverse outcomes in patients with PH [21-23]. Kawut et
al. showed, in a retrospective cohort of 84 patients with
PAH, that radionuclide angiography-derived-RVEF is
independently associated with mortality [23]. Obvious
advantages of using CMR-derived RVEF over nuclear-
derived RVEF to risk stratify PH patients are that no
intravenous line is needed and there is no exposure to
ionizing radiation. The thin free wall of the RV and the
extensive trabeculation of the chamber can make quan-
titative assessment of the RVEF challenging. In addition,
it requires some expertise to accurately define the most
b a s a ls h o r t - a x i ss l i c eo ft h eR V .D e s p i t et h i s ,t h er e p r o -
ducibility of CMR-derived RVEF is excellent and it is
generally regarded as the reference standard for the
measurement of RV size and function [6].
In the only other publication studying the prognostic
significance of CMR variables in patients with PH, van
Wolferen et al. performed CMR, right heart catheteriza-
tion, and the six minute walk test at baseline and 1-year
later in patients with idiopathic pulmonary arterial
hypertension [21]. They found that stroke volume index,
right ventricular end-diastolic volume index, and left
ventricular end-diastolic volume index were independent
predictors of mortality and treatment failure at baseline
but RVEF was not. This discrepancy in results might be
due to the fact that we included multiple etiologies of
PH in our study or that the length of our follow-up was
different. In addition, in their study, RVEF was calcu-
lated by dividing stoke volume (which was obtained
using velocity-encoded imaging of the pulmonary artery)
by RVEDV. This difference in methods for calculating
RVEF likely explains the discrepancy in our results.
Nevertheless, both studies c o n f i r mt h a tC M Rp r o v i d e s
meaningful information, particularly about the right ven-
tricle, that can help risk stratify patients so that they
may receive appropriate management.
Suspected etiology of RVIP-LGE
The cause of RVIP-LGE in patients with PH remains to
be fully elucidated. Myocardial infarction is highly unli-
kely, given the atypical pattern and focal distribution of
RVIP-LGE. Although several studies have shown reversi-
ble ischemia in the right ventricle, particularly in PH
patients with elevated pulmonary pressures, none have
shown fixed perfusion defects in the RVIP [24]. Myocar-
dial fibrosis due to mechanical stress and strain of the
RVIP with elevated RV pressures has previously been
implicated [7]. However, others have suggested that
RVIP-LGE may represent myocardial disarray rather
than fibrosis [25]. Indeed, Bradlow et al. examined the
heart of a patient with idiopathic pulmonary arterial
hypertension at autopsy who had evidence of RVIP-LGE
[26]. They found increased collagen and fat between
fiber bundles (plexiform fibrosis) consistent with myo-
cardial disarray, but no pathologic fibrosis. Disarray is
common in the RVIP even in healthy patients but
becomes exaggerated in the presence of RV hypertrophy
and dilatation and, thus, allows for more contrast pool-
i n g .T h i sm a yb et h er e a s o nw h yt h e n ,i no u rs t u d y ,
RVIP-LGE was associated with larger right ventricular
volume and mass but failed to add prognostic value
over known independent markers for death and treat-
ment failure. Another potential explanation for RVIP-
LGE includes partial volume effect created by contrast
trapped within the extensive trabeculation of the dilated
RV cavity adjacent to the actual RVIP rather than within
the actual myocardium itself.
Limitations
One important limitation of our study is that only a
subset of patients underwent right heart catheterization,
Freed et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:11
http://www.jcmr-online.com/content/14/1/11
Page 7 of 9NT-proBNP testing and/or functional testing within 4
months of their CMR exam. However, we felt it impor-
tant to include these data (despite the above limitation)
in our analysis because PH is a rare disorder with lim-
ited opportunities for study and that it would be impor-
tant to define the prognostic value of CMR within the
context of other clinically relevant variables. Another
important limitation of our study is that we were unable
to reliably quantify the amount RVIP-LGE due to partial
volume effect, preventing us from accurately defining
the borders of hyperenhancement in every patient. We
believe, however, that there is significant clinical utility
in being able to easily visualize the presence of RVIP-
LGE and using it as a marker for detecting more severe
disease and worse outcomes.
Conclusion
Contrast-enhanced CMR may be a useful tool in the
management of patients with PH. RVIP-LGE is a readily
visible, non-invasive marker associated with more
advanced PH, as reflected by its association with larger
RV volumes and greater RV mass, reduced RVEF, and
higher mPAP. Patients with RVIP-LGE are significantly
more likely to worsen clinically than those without this
marker. Additionally, CMR-derived RVEF is an indepen-
dent predictor of adverse outcomes in patients with PH
and its ability to risk stratify PH patients is similar to
that of mPAP and METs. As new medications for PH
are developed and patients with this disease are treated
earlier in their disease course, contrast-enhanced CMR
could potentially help in risk stratification so that appro-
priate therapy can be given in a timely manner.
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